ArticleFrontiers in digital health2026
From voice biomarkers to telemedicine screening: developing and evaluating a voice-based AI model for laryngeal lesion detection using the Bridge2AI-Voice dataset.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: The human voice contains rich acoustic information indicative of laryngeal pathology, yet current screening relies on resource-intensive in-person laryngoscopy. While artificial intelligence has shown promise for voice analysis, progress has been limited by small, inconsistent datasets and challenges to clinical translation. The Bridge2AI-Voice initiative addresses these barriers by providing a large-scale, ethically sourced dataset with standardized, privacy-preserving derived features. Objective: To determine whether the derived-feature release of Bridge2AI-Voice v3.0.0 can support a high-sensitivity screening model for laryngeal lesions and to evaluate its translational readiness using telemedicine implementation frameworks. Methods: We analyzed data from 205 adult participants (136 controls, 52 benign vocal fold lesions, 13 precancerous lesions, 4 laryngeal cancer) drawn from the Bridge2AI-Voice v3.0.0 derived-feature release. An L2-regularized logistic regression model was fit to 131 OpenSMILE static acoustic features with age and sex at birth, evaluated under participant-level stratified 10-fold nested cross-validation. Inner-fold cross-validation was used for operating-point threshold selection. Pre-specified validity tests against age confounding included a DeLong comparison against an age-only baseline and an age-stratified label permutation test. Alternative feature modalities (SPARC articulatory features, Mel spectrogram derivatives, and multimodal combinations) and alternative classifier families were evaluated as robustness checks. Results: The OpenSMILE-based model achieved cross-validated AUC 0.812 (95% CI 0.744-0.876), with operating-point sensitivity 0.870 (95% CI 0.767-0.939) and specificity 0.566 (95% CI 0.479-0.651). Model discrimination significantly exceeded an age-only baseline (DeLong Conclusions: Derived acoustic features from the Bridge2AI-Voice v3.0.0 release combined with basic demographic information support cross-validated discrimination of vocal fold lesions consistent with the upper range of published voice-based laryngeal pathology classifiers. The result is presented as a candidate signal warranting confirmatory investigation in a larger, prospectively recruited cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.